Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ESRRB | O95718 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESRRA | P11474 | 1/20 | 0.45 |
| ▸ | ESRRG | P62508 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490516 | 0.91 | MAPT (0.52) | LMNAMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL16528279 | 0.88 | SMN1; SMN2 (0.46) | LMNAMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL16528113 | 0.88 | LMNA (0.49) | LMNAMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL24847031 | 0.87 | MAPT (0.56) | LMNAMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL23456158 | 0.86 | SMN1; SMN2 (0.53) | LMNAMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL19404282 | 0.86 | KMT2A (0.51) | LMNAMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL19404303 | 0.85 | MAPT (0.47) | LMNAMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL27097509 | 0.85 | MEN1 (0.50) | LMNAMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL24847153 | 0.84 | LMNA (0.48) | LMNAMAPTALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL23456293 | 0.83 | STS (0.49) | LMNAMAPTALDH1A1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-08-08 | — | — | US | disclosed |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11542254-B2 | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors | UNIVERSISITY OF UTAH RESEARCH FOUNDATION (US) | 2023-01-03 | — | — | US | disclosed |
| EP-3612520-B1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMA (KR) | 2021-11-10 | — | — | EP | disclosed |
| US-20210188790-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2021-06-24 | — | — | US | disclosed |
| US-20210171502-A1 | METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS | UNITED STATES GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
| US-10988449-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-27 | — | — | US | disclosed |
| US-20200115349-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2020-04-16 | — | — | US | disclosed |
| EP-3612520-A1 | AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF | Il Dong Pharmaceutical Co., Ltd. (KR) | 2020-02-26 | — | — | EP | disclosed |
| CN-110678450-A | Isoxazole derivatives as nuclear receptor agonists and uses thereof | 日东制药株式会社 | 2020-01-10 | — | — | CN | disclosed |
| WO-2018190643-A1 | AN ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USED THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2018-10-18 | — | — | WO | disclosed |
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1750727-A2 | KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005117909-A2 | KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171502-A1 | METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS | BCL9, BCL9L, BCL3 | LMNA 798/4885MAPT 2998/4885ALDH1A1 3463/4885 |
| US-20200115349-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | LMNA 4329/4885MAPT 3481/4885ALDH1A1 2667/4885 |
| US-11542254-B2 | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors | BCL9, BCL9L, BCL3 | LMNA 799/4885MAPT 3080/4885ALDH1A1 3240/4885 |
| US-20210188790-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | LMNA 3292/4885MAPT 4496/4885ALDH1A1 840/4885 |
| US-10988449-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | LMNA 4329/4885MAPT 3481/4885ALDH1A1 2667/4885 |
| US-20240262799-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | LMNA 3644/4885MAPT 3807/4885ALDH1A1 1135/4885 |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | LMNA 3292/4885MAPT 4496/4885ALDH1A1 840/4885 |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | LMNA 2304/4885MAPT 4051/4885ALDH1A1 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.